Artur Katz

Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined

Everardo D. Saad, Artur Katz · Annals of Oncology · 2008 · 112 citations · Full text

Medicine, Oncology, Breast Oncology +11

Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine

Everardo D. Saad, Marcel Cerqueira César Machado, Dalia Wajsbrot et al. · International Journal of Gastrointestinal Cancer · 2002 · 111 citations

Medicine, Oncology, Chemotherapy +13

Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC

Franciele Hinterholz Knebel, Fabiana Bettoni, Andrea Kazumi Shimada et al. · Lung Cancer · 2017 · 75 citations

Medicine, Molecular Biology, Molecular Genetics +13

Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient

Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni et al. · npj Precision Oncology · 2021 · 42 citations · Full text

Medicine, Oncology, Pharmacology +16

A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration

Artur Katz, Sidnei Epelman, Agnaldo Anelli et al. · Journal of Cancer Research and Clinical Oncology · 1995 · 33 citations · Full text

Medicine, Oncology, Pharmacology +6